

Table D2: Population characteristics –CRT P effectiveness

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
Abraham,2002 ² 7 MIRACLE	Arm 1(Control group):225	F: 72(32) W:205(91)	Mean: 64.7 Med: NR Range: NR SD: 11.2	131(58)	NR	Mean: 165 Med: NR Range: NR SD: 20	NR	III: 205(91)	Mean: 21.6 Med: NR Range: NR SD: 6.2	Creat: NR GFR: NR
	Arm 2(Cardiac Resynchronization Group):228	F: 73(32) W:205(90)	Mean: 63.9 Med: NR Range: NR SD: 10.7	114(50)	NR	Mean: 167 Med: NR Range: NR SD: 21	NR	III: 205(90)	Mean: 21.8 Med: NR Range: NR SD: 6.3	Creat: NR GFR: NR
Cleland,2004 ¹ CARE-HF	Arm 1(Medical Therapy Alone):404	F: 111(27) NR	Mean: NR Med: 66 Range: NR SD: NR	144(36)	NR	Mean: NR Med: 160 Range: 152-180 SD: NR	NR	IV: 27(7)	Mean: NR Med: 25 Range: NR SD: NR	Creat: NR GFR: 61ml/min/1.73m ²
	Arm 2(Medical Therapy plus Cardiac Resynchronization(CRT-P)):409	F: 105(26) NR	Mean: NR Med: 67 Range: NR SD: NR	165(40)	NR	Mean: NR Med: 160 Range: 152-180 SD: NR	NR	IV: 23(6)	Mean: NR Med: 25 Range: NR SD: NR	Creat: NR GFR: 60ml/min/1.73m ²
Cleland,2006 ² CARE HF Sub Study	Arm 1(Medical Therapy Alone):404	F: 109(27) NR	Mean: 66 Med: NR Range: 59-72 SD: NR	144(36)	NR	Mean: 160 Med: NR Range: 152-180 SD: NR	NR	III: 377(93)	Mean: NR Med: 25 Range: NR SD: NR	Creat: NR GFR: NR
	Arm 2(CRT):409	F: 106(26) NR	Mean: 67 Med: NR Range: 60-73 SD: NR	165(40)	NR	Mean: 160 Med: NR Range: 152-180 SD: NR	NR	III: 386(94)	Mean: NR Med: 25 Range: NR SD: NR	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
Cleland,2007 ³ CARE HF Sub Study	Arm 1(Medical therapy alone):404	F: 111(27) NR	Mean: 66 Med: NR Range: 59- 72 SD: NR	142(35)	NR	Mean: NR Med: 160 Range: 152- 180 SD: NR	NR	IV: 27(7)	Mean: NR Med: 25 Range: 22- 29 SD: NR	Creat: NR GFR: 61ml/min
	Arm 2(CRT- P):409	F: 105(26) NR	Mean: 67 Med: NR Range: 60- 73 SD: NR	167(41)	NR	Mean: NR Med: 160 Range: 152- 180 SD: NR	NR	IV: 23(6)	Mean: NR Med: 25 Range: 21- 29 SD: NR	Creat: NR GFR: 60ml/min
Cleland,2012 ⁵ CARE HF Sub Study	Arm 1(No CRT):404	F: 109(27) NR	Mean: 66 Med: NR Range: 59- 72 SD: NR	144(36)	NR	Mean: 160 Med: NR Range: 152- 180 SD: NR	NR	III: 377(93)	Mean: Med: 25 Range: SD:	Creat: NR GFR: NR
	Arm 2(CRT):409	F: 106(26) NR	Mean: 67 Med: NR Range: 60- 73 SD: NR	165(40)	NR	Mean: 160 Med: NR Range: 152- 180 SD: NR	NR	III: 386(94)	Mean: Med: 25 Range: SD:	Creat: NR GFR: NR
Leclercq,2007 ⁴⁴	Arm 1(BiV First):25	F: 0(0) NR	Mean: 73 Med: NR Range: NR SD: 9.3	14(56)	14(56)	Mean: 212 Med: NR Range: NR SD: 28	NR	NR	Mean: 24 Med: NR Range: NR SD:	Creat: NR GFR: NR
	Arm 1(RV First):19	F: 4(21.1) NR	Mean: 74 Med: NR Range: NR SD: 6	9(47.4)	7(36.8)	Mean: 199 Med: NR Range: NR SD: 21	NR	NR	Mean: 27 Med: NR Range: NR SD:	Creat: NR GFR: NR
	Arm 1(BiV First):25	F: 0(0) NR	Mean: 73 Med: NR Range: NR SD: 9.3	14(56)	14(56)	Mean: 212 Med: NR Range: NR SD: 28	NR	NR	Mean: 24 Med: NR Range: NR SD:	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
	Arm 1(RV First):19	F: 4(21.1) NR	Mean: 74 Med: NR Range: NR SD: 6	9(47.4)	7(36.8)	Mean: 199 Med: NR Range: NR SD: 21	NR	NR	Mean: 27 Med: NR Range: NR SD:	Creat: NR GFR: NR
	Overall(All Patients):44	F: 4(9.1) NR	Mean: 73 Med: NR Range: NR SD: 8	23(52.3)	21(47.7)	Mean: 206 Med: NR Range: NR SD: 26	NR	NR	Mean: 25 Med: NR Range: NR SD:	Creat: NR GFR: NR
	Overall(All Patients):44	F: 4(9.1) NR	Mean: 73 Med: NR Range: NR SD: 8	23(52.3)	21(47.7)	Mean: 206 Med: NR Range: NR SD: 26	NR	NR	Mean: 25 Med: NR Range: NR SD:	Creat: NR GFR: NR
Pokushalov,2010 ⁴³	Arm 1(All patients):178	F: 18(10) NR	Mean: 62.8 Med: NR Range: NR SD: 7	NR	NR	Mean: 139 Med: NR Range: NR SD: 28	NR	NR	Mean: 29 Med: NR Range: NR SD:	Creat: NR GFR: NR
	Arm 1(CABG):87	F: 7(8) NR	Mean: 64 Med: NR Range: NR SD: 5	NR	NR	Mean: 144 Med: NR Range: NR SD: 28	NR	NR	Mean: 30 Med: NR Range: NR SD:	Creat: NR GFR: NR
	Arm 2(CABG+CRT) :91	F: 8(9) NR	Mean: 62 Med: NR Range: NR SD: 4	NR	NR	Mean: 137 Med: NR Range: NR SD: 29	NR	NR	Mean: 28 Med: NR Range: NR SD:	Creat: NR GFR: NR
Sutton,2003 ²⁸ MIRACLE Sub Study	Arm 1(Control group):151	F: 47(31.1) W:136(90.1) AA:NR O:NR	Mean: 64.8 Med: NR Range: NR SD: 11.4	NR	NR	Mean: 164.7 Med: NR Range: NR SD: 20.6	NR	III: 143(94.7)	Mean: 24.3 Med: NR Range: NR SD: 6.8	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
	Arm 2(CRT group(CRT- P)):172	F: 60(34.9) W:155(90.1) AA:NR O:NR	Mean: 63.9 Med: NR Range: NR SD: 11	NR	NR	Mean: 166.4 Med: NR Range: NR SD: 19.7	NR	III: 155(90.1)	Mean: 24.5 Med: NR Range: NR SD: 6.8	Creat: NR GFR: NR
Wikstrom,2009 ⁸ CARE HF Sub Study	Medical therapy alone	111(27)	Mean: 66 Med: NR Range: NR SD: NR	142(35)	NR	Mean: 160 Med: NR Range: 152- 180 SD: NR	NR	IV:27(7)	Mean: NR Med: 25 Range:22- 29 SD:NR	Creat: NR GFR: 61ml/min
	CRT-P	105(26)	Mean: 67 Med: NR Range: NR SD: NR	167(41)	NR	Mean: 160 Med: NR Range: 152- 180 SD: NR	NR	IV:(23(6)	Mean: NR Med: 25 Range:21- 29 SD:NR	Creat: NR GFR:60ml/ min
Ghio, 2009 ⁶ CARE HF Sub Study	CRT	90(NR)	Mean: 67 Med: NR Range:59- 73 SD: NR	168(46)	NR	Mean: 160 Med: NR Range: 152- 180 SD: NR	NR	IV:(23(6)	Mean: NR Med: NR Range:NR SD:NR	Creat: NR GFR: NR
	Medical Therapy	102(NR)	Mean: 66 Med: NR Range: 59- 73 SD: NR	135(36)	NR	Mean: 160 Med: NR Range: 152- 180 SD: NR	NR	IV:(23(6)	Mean: NR Med: NR Range:NR SD:NR	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
Bristow,2004 ²⁹ COMPANION	Arm 1(Optimal Pharmacologic Therapy):308	F: 96(31) NR	Mean: 68 Med: NR Range: NR SD: NR	NR(59)	NR	Mean: 158 Med: NR Range: NR SD: NR	LBBB:NR(70) RBBB: NR(9) IVCD: NR PBBBlock: NR	III: NR(82)	Mean: 22 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
	Arm 2(CRT- P):617	F: 203(33) NR	Mean: 67 Med: NR Range: NR SD: NR	NR(54)	NR	Mean: 160 Med: NR Range: NR SD: NR	LBBB:NR(69) RBBB:NR(12) IVCD: NR PBBBlock: NR	III: NR(87)	Mean: 20 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
	Arm 3(CRT- D):595	F: 196(33) NR	Mean: 66 Med: NR Range: NR SD: NR	NR(55)	NR	Mean: 160 Med: NR Range: NR SD: NR	LBBB:NR(73) RBBB:NR(10) IVCD: NR PBBBlock: NR	III: NR(86)	Mean: 22 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
Anand, 2009 ³⁰ COMPANION Sub Study	Arm 1(OPT):308	F: 96(31) NR	Mean: NR Med: 68 Range: NR SD: NR	NR(59)	NR	Mean: NR Med: 158 Range: NR SD: NR	NR	III: NR(82)	Mean: 22 Med: NR Range: NR SD: NR	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
	Arm 2(CRT- P):617	F: 203(33) NR	Mean: NR Med: 67 Range: NR SD: NR	NR(54)	NR	Mean: NR Med: 160 Range: NR SD: NR	NR	III: NR(87)	Mean: 20 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
	Arm 3(CRT- D):595	F: 196(33) NR	Mean: NR Med: 66 Range: NR SD: NR	NR(55)	NR	Mean: NR Med: 160 Range: NR SD: NR	NR	III: NR(86)	Mean: 22 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
Carson,2005 ³¹ COMPANION Sub Study	Arm 1(Optimal Pharmacologic al therapy):308	F: 96(31) NR	Mean: 68 Med: NR Range: NR SD: NR	NR(59)	NR	Mean: 158 Med: NR Range: NR SD: NR	LBBB:NR(70) RBBB: NR(9) IVCD: NR PBBBlock: NR	III: NR(82)	Mean: 22 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
	Arm 2(CRT- P):617	F: 203(33) NR	Mean: 67 Med: NR Range: NR SD: NR	NR(54)	NR	Mean: 160 Med: NR Range: NR SD: NR	LBBB:NR(69) RBBB:NR(12) IVCD: NR PBBBlock: NR	III: NR(87)	Mean: 20 Med: NR Range:NR SD: NR	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
	Arm 3(CRT- D):595	F: 196(33) NR	Mean: 66 Med: NR Range: NR SD: NR	NR(55)	NR	Mean: 160 Med: NR Range: NR SD: NR	LBBB:NR(73) RBBB:NR(10) IVCD: NR PBBBlock: NR	III: NR(86)	Mean: 22 Med: NR Range: NR SD: NR	Creat: NR GFR: NR
Cleland,2009 ⁴ CARE HF Sub Study	Overall(Medic al therapy alone):404	F: 111(27) NR	Mean: 66 Med: NR Range: 59- 72 SD: NR	142(35)	NR	Mean: NR Med: 160 Range: 152- 180 SD: NR	NR	IV: 27(7)	Mean: NR Med: 25 Range: 22- 29 SD: NR	Creat: NR GFR: 61ml/min
	Overall(CRT- P):409	F: 105(26) NR	Mean: 67 Med: NR Range: 60- 73 SD: NR	167(41)	NR	Mean: NR Med: 160 Range: 152- 180 SD: NR	NR	III: NR IV: 23(6)	Mean: NR Med: 25 Range: 21- 29 SD: NR	Creat: NR GFR: 60ml/min
Cazeau,2001 ³² MUSTIC	All patients	F: 17(25.4) NR	Mean: 63 Med: NR Range: NR SD: 10	NR	NR	Mean: 176 Med: NR Range: NR SD: 19	LBBB:NR(87) RBBB:NR(10) IVCD: NR PBBBlock: NR	III: 67(100)	Mean: 23 Med: NR Range: NR SD: 7	Creat: NR GFR: NR

Author,Year Trial	Arm (arm name): n(%)	Female, n (%) Race, n(%)	Age (years) Mean, median, range	Ischemic cardiomyopathy, n (%)	Atrial fibrillation, n (%)	QRS interval, Mean, median, range	QRS morphology - LBBB, n(%) RBBB, n(%) IVCD, n(%) PBBBlock, n(%)	NYHA class, n(%)	LVEF, Mean, median, range, SD	Creatinine GFR
	All patients	F: 8(17.8) NR	Mean: 66 Med: NR Range: NR SD: 9	NR	45(100)	Mean: 207 Med: NR Range: NR SD: 17	NR	III: 45(100)	Mean: 25 Med: NR Range: NR SD: 10	Creat: NR GFR: NR

F-Female, W-White, AA-African American, O-Others, NR-Not Reported, SD-Standard Deviation, Med-Median, n-Number, LBBB-Left Bundle Branch Block, RBBB-Right, Bundle Branch Block, IVCD-Intra Ventricular Conduction Delay, PBBBlock-Paced Bundle Branch Block, NYHA-New York Heart Association, LVEF-Left Ventricular Ejection Fraction, GFR-Glomerular Filtration Rate